艾伯维公司(AbbVie)宣布,其三期临床研究成功达成主要终点,与安慰剂相比,展现出统计学意义上的显著改善。这一结果标志着该药物研发进程中的关键里程碑。
艾伯维公司(AbbVie)宣布,其三期临床研究成功达成主要终点,与安慰剂相比,展现出统计学意义上的显著改善。这一结果标志着该药物研发进程中的关键里程碑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.